Description

D[LEU4,LYS8]-VP TFA is a selective agonist of vasopressin V1b receptor, with the Kis of 0.16 nM, 0.52 nM, and 0.1.38 nM for rat, human and mouse V1b receptor, respectively. D[LEU4,LYS8]-VP TFA has weak antidiuretic, vasopressor, and in vitro oxytocic activities[1][2].–80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture)–Neuroscience-Neuromodulation–C49H68F3N11O13S2—-[1]Ana P, et, al. Pharmacological and physiological characterization of d[Leu4, Lys8]vasopressin, the first V1b-selective agonist for rat vasopressin/oxytocin receptors. Endocrinology. 2007 Sep; 148(9): 4136-46.|[2]Ana P, et, al. Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasopressin at positions 4 and 8. J Med Chem. 2007 Feb 22; 50(4): 835-47.—-1140.25–98.36–O=C(O)C(F)(F)F.CC(C)C[C@@H]1NC([C@H](CC2=CC=CC=C2)NC([C@H](CC3=CC=C(O)C=C3)NC(CCSSC[C@H](NC([C@H](CC(N)=O)NC1=O)=O)C(N4CCC[C@H]4C(N[C@@H](CCCCN)C(NCC(N)=O)=O)=O)=O)=O)=O)=O–Neurological Disease; Cardiovascular Disease–DMSO : ≥ 100 mg/mL|H2O : 100 mg/mL (ultrasonic)–Vasopressin Receptor–V1b Receptor –GPCR/G Protein–Peptides